• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

    2/11/25 8:30:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNM alert in real time by email

    Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors

    Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately.

    "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant clinical needs with a fundamentally new approach for the most intractable diseases. As we rapidly build our pipeline, with our lead program already in clinical testing in patients, we believe the time is right for new leadership to guide the next stages of Aro's growth," noted Dr. Dillon. "Purnanand brings deep experience in industry and a proven track record of success in drug development across multiple therapeutic areas, and in scaling platforms, to his new role at Aro Biotherapeutics. I look forward to collaborating with him and the Aro Board to realize the company's long-term goals."

    Dr. Sarma will be responsible for the further development of Aro's pipeline of siRNA-conjugate medications, including the company's lead product candidate ABX1100, a novel Centyrin-GYS1 short-interfering RNA (siRNA) drug conjugate for the treatment of Pompe disease, while preparing the company for its next stage of value creation.

    "I am honored to take on the leadership of Aro at this pivotal point in the company's evolution," said Dr. Sarma. "The company has a rare opportunity to make a significant clinical impact across multiple therapeutic areas using what I consider as a disruptive approach. I look forward to building upon the success of Sue and the rest of the Aro team to unleash the potential of a new class of siRNA drugs for a wide range of diseases, starting with their lead program in Pompe disease."

    Dr. Sarma's pharmaceutical experience spans more than three decades, with an extensive background in drug development, from discovery through approval, and a robust track record of value creation, including initial public offerings (IPOs), mergers and acquisitions (M&A), and asset and company transactions. He has more than 13 years of experience as an operating CEO and board member for both private and public companies, most recently as CEO for Immunome (NASDAQ:IMNM).

    Prior to Immunome, Dr. Sarma led TARIS Biomedical as its CEO through the sale of its first program for interstitial cystitis to Allergan, and before the company was acquired by Johnson & Johnson in 2019. Prior to his CEO roles, he also held positions of increasing responsibility at Cephalon Corporation, Nektar Therapeutics, and SmithKline Beecham Pharmaceuticals. Dr. Sarma has a Ph.D. in Pharmaceutics from the University of Minnesota and a Bachelor of Pharmacy (BPharm) degree from Andhra University in Visakhapatnam, India.

    "Purnanand's unique combination of extensive strategic and operational experience, coupled with deep pharmaceutical knowledge, makes him a market-leading candidate for leadership positions across the industry," added Kevin Raidy, Board member of Aro and senior managing director and head of Healthcare Opportunities at Blue Owl Capital. "The fact that he chose to join Aro is a validation of the exciting possibilities inherent in our platform and lead asset."

    Dr. Dillon co-founded Aro Biotherapeutics in 2018 along with Karyn O'Neil, Ph.D., the company's chief scientific offer and co-inventor of the company's proprietary Centyrin technology. Dr Dillon's career has been marked by leading cross-disciplinary teams to discover and develop novel therapeutics. Prior to joining Aro, she spent 16 years at Centocor and Janssen Pharmaceuticals, leading global Immunology R&D, achieving numerous regulatory approvals for innovative antibody products for autoimmune diseases, and was named one of the "Fierce Women in Biotech" in 2013 and 2022.

    About Aro Biotherapeutics

    Aro Biotherapeutics is a biotechnology company working to develop potent and versatile tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly owned pipeline of Centyrin-based therapeutic candidates for tissue-specific targeting of therapeutics for a diverse set of diseases. For more information, visit www.arobiotx.com.

    About ABX1100​

    ABX1100, an investigational treatment for Pompe disease, is comprised of a CD71 receptor-binding Centyrin conjugated to a short-interfering RNA (siRNA) that specifically interferes with expression of GYS1 messenger RNA (mRNA), thereby reducing levels and overall activity of the GYS1 enzyme in muscle tissues. ABX1100 was well tolerated in a recently completed Phase 1 trial conducted in normal healthy volunteers, and demonstrated durable GYS1 mRNA knockdown in muscle biopsies, supporting the potential for quarterly dosing. ABX1100 has received Orphan Drug Designation and Rare Pediatric Disease status from the United States Food and Drug Administration (FDA).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250211732563/en/

    Media

    SmithSolve

    Corey Carmichael

    (862) 260-7929

    [email protected]

    Get the next $IMNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMNM

    DatePrice TargetRatingAnalyst
    4/2/2025$23.00Buy
    Lake Street
    11/8/2024$30.00Overweight
    Stephens
    5/31/2024$27.00Overweight
    Piper Sandler
    4/30/2024$24.00Overweight
    JP Morgan
    4/15/2024$35.00Buy
    Guggenheim
    1/29/2024$30.00Outperform
    Leerink Partners
    12/19/2023$12.00Outperform
    Wedbush
    10/29/2021$35.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $IMNM
    Financials

    Live finance-specific insights

    See more
    • Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

      Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th

      3/28/24 4:02:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Third Quarter 2023 Financial Results

      - Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

      11/9/23 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

      Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p

      3/16/23 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    SEC Filings

    See more

    $IMNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IMNM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IMNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form DEFA14A filed by Immunome Inc.

      DEFA14A - Immunome Inc. (0001472012) (Filer)

      4/24/25 4:07:28 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Immunome Inc.

      DEF 14A - Immunome Inc. (0001472012) (Filer)

      4/24/25 4:05:30 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Immunome Inc.

      S-8 - Immunome Inc. (0001472012) (Filer)

      3/19/25 5:10:27 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 164,500 shares of common stock to nine new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $8.8

      5/2/25 4:01:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first

      4/4/25 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 228,000 shares of common stock to five new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $6

      4/3/25 4:05:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bienaime Jean Jacques bought $60,684 worth of shares (7,800 units at $7.78), increasing direct ownership by 33% to 31,415 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:05:21 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Siegall Clay B bought $999,459 worth of shares (137,100 units at $7.29), increasing direct ownership by 20% to 806,736 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:03:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bienaime Jean Jacques bought $57,470 worth of shares (7,000 units at $8.21), increasing direct ownership by 42% to 23,615 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/25/25 5:18:02 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Immunome with a new price target

      Lake Street initiated coverage of Immunome with a rating of Buy and set a new price target of $23.00

      4/2/25 8:05:05 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Immunome with a new price target

      Stephens initiated coverage of Immunome with a rating of Overweight and set a new price target of $30.00

      11/8/24 8:17:18 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Immunome with a new price target

      Piper Sandler initiated coverage of Immunome with a rating of Overweight and set a new price target of $27.00

      5/31/24 7:43:20 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunome Inc.

      SC 13G/A - Immunome Inc. (0001472012) (Subject)

      11/14/24 9:00:58 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immunome Inc.

      SC 13G - Immunome Inc. (0001472012) (Subject)

      11/14/24 1:28:33 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immunome Inc.

      SC 13G - Immunome Inc. (0001472012) (Subject)

      11/14/24 10:33:51 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Higgins Jack exercised 5,200 shares at a strike of $1.35, increasing direct ownership by 38% to 18,729 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/28/25 5:54:02 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bienaime Jean Jacques bought $60,684 worth of shares (7,800 units at $7.78), increasing direct ownership by 33% to 31,415 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:05:21 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Siegall Clay B bought $999,459 worth of shares (137,100 units at $7.29), increasing direct ownership by 20% to 806,736 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:03:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

      Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant

      2/11/25 8:30:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Appoints Roee Shahar as Executive Vice President, Commercial

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.

      10/8/24 8:05:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

      Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an

      7/9/24 7:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care